{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:29:07Z","timestamp":1793636947635,"version":"4.5.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.ymgme.2010.05.001","type":"journal-article","created":{"date-parts":[[2010,5,6]],"date-time":"2010-05-06T06:01:04Z","timestamp":1273125664000},"page":"309-315","source":"Crossref","is-referenced-by-count":49,"title":["Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease"],"prefix":"10.1016","volume":"100","author":[{"given":"Karen M.","family":"Ashe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuming","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varvara","family":"Jingozyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick F.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.F.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Lien","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Mattaliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald K.","family":"Scheule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.","family":"Moreland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2010.05.001_bib1","series-title":"The Metabolic and Molecular Bases of Inherited Disease","article-title":"Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.ymgme.2010.05.001_bib2","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2010.05.001_bib3","unstructured":"Myozyme prescribing information. Genzyme Corporation Available at: <www.Myozyme.com>."},{"key":"10.1016\/j.ymgme.2010.05.001_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1055\/s-2005-837543","article-title":"Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study","volume":"36","author":"Klinge","year":"2005","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.ymgme.2010.05.001_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10545-007-0519-9","article-title":"Glycogen storage disease types I and II: treatment updates","volume":"30","author":"Koeberl","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2010.05.001_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00125817-200103000-00008","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2010.05.001_bib7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/mus.10381","article-title":"Morphological changes in muscle tissue of patients with infantile Pompe\u2019s disease receiving enzyme replacement therapy","volume":"27","author":"Winkel","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2010.05.001_bib8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2010.05.001_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2010.05.001_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alfa prolongs long term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2010.05.001_bib11","first-page":"155","article-title":"LBS2.001 Results from a randomized, double-blind, multicenter, multinational, placebo-controlled study of the safety and efficacy of myozyme, recombinant human acid alpha-glucosidase (rhGAA), for the treatment of Pompe disease in juveniles and adults","volume":"71","author":"van der Ploeg","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2010.05.001_bib12","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","author":"Strothotte","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2010.05.001_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.rmed.2008.12.009","article-title":"Pompe disease: a neuromuscular disease with respiratory muscle involvement","volume":"103","author":"Mellies","year":"2009","journal-title":"Respir. Med."},{"key":"10.1016\/j.ymgme.2010.05.001_bib14","doi-asserted-by":"crossref","first-page":"43R","DOI":"10.1093\/glycob\/cwi076","article-title":"Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses","volume":"15","author":"Butters","year":"2005","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgme.2010.05.001_bib15","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/hmg\/ddp535","article-title":"Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease","volume":"19","author":"Douillard-Guilloux","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2010.05.001_bib16","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1093\/hmg\/ddn290","article-title":"Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II","volume":"17","author":"Douillard-Guilloux","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2010.05.001_bib17","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2010.05.001_bib18","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1074\/jbc.271.9.5033","article-title":"Regulation of both glycogen synthase and PHAS-I by insulin in rat skeletal muscle involves mitogen-activated protein kinase-independent and rapamycin-sensitive pathways","volume":"271","author":"Azpiazu","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2010.05.001_bib19","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1074\/jbc.274.2.776","article-title":"Control of glycogen synthesis in cultured human muscle cells","volume":"274","author":"Halse","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2010.05.001_bib20","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.metabol.2006.08.002","article-title":"Rapamycin-mediated inhibition of mammalian target of rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation","volume":"55","author":"Sipula","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.ymgme.2010.05.001_bib21","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1074\/jbc.M004812200","article-title":"Regulation of glycogen synthesis by amino acids in cultured human muscle cells","volume":"276","author":"Armstrong","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2010.05.001_bib22","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1128\/MCB.00980-08","article-title":"The TSC-mTOR Pathway Mediates Translational Activation of TOP mRNAs by Insulin Largely in a Raptor- or Rictor-Independent Manner","volume":"29","author":"Patursky-Polischuk","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ymgme.2010.05.001_bib23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drudis.2006.12.008","article-title":"Targeting mammalian target of rapamycin (mTOR) for health and diseases","volume":"12","author":"Tsang","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymgme.2010.05.001_bib24","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.ymgme.2010.05.001_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/13813450902778171","article-title":"Regulation of muscle glycogen synthase phosphorylation and kinetic properties by insulin. Exercise, adrenaline and role in insulin resistance","volume":"115","author":"Jensen","year":"2009","journal-title":"Arch Physiol. Biochem."},{"key":"10.1016\/j.ymgme.2010.05.001_bib26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1083\/jcb.200903131","article-title":"Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy","volume":"187","author":"Risson","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ymgme.2010.05.001_bib27","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1073\/pnas.0914798107","article-title":"Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis","volume":"107","author":"Li","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ymgme.2010.05.001_bib28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2010.05.001_bib29","unstructured":"Rapamune prescribing information. Wyeth Pharmaceuticals Inc., Available at: <http:\/\/www.wyeth.com\/content\/showlabeling.asp?id=139>."},{"key":"10.1016\/j.ymgme.2010.05.001_bib30","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2010.05.001_bib31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ceb.2009.01.024","article-title":"mTOR and the control of whole body metabolism","volume":"21","author":"Polak","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ymgme.2010.05.001_bib32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe\u2019s disease N","volume":"360","author":"Mendelsohn","year":"2009","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.ymgme.2010.05.001_bib33","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1093\/hmg\/ddn292","article-title":"Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease","volume":"17","author":"Raben","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2010.05.001_bib34","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.cmet.2007.11.001","article-title":"FoxO3 controls autophagy in skeletal muscle in vivo","volume":"6","author":"Mammucari","year":"2007","journal-title":"Cell Metabol."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719210001824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719210001824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T04:59:58Z","timestamp":1544504398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719210001824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S1096719210001824"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2010.05.001","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}